(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 December 2012 (06.12.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/163932 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 5/00* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/EP2012/060078

(22) International Filing Date:
31 May 2012 (31.05.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
11168644.0 3 June 2011 (03.06.2011) EP

(71) Applicant *(for all designated States except US)*: **BAYER INTELLECTUAL PROPERTY GMBH** [DE/DE]; Alfred-Nobel-Str. 10, 40789 Monheim (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FREIBERG, Christoph** [DE/DE]; Nüller Str. 83, 42115 Wuppertal (DE). **OTTO, Christiane** [DE/DE]; Monbijouplatz 9, 10178 Berlin, 10178 Berlin (DE). **LINDEN, Lars** [DE/DE]; Bruchstr. 72, 40235 Düsseldorf (DE). **HARRENGA, Axel** [DE/DE]; Sadowastr. 17, 42115 Wuppertal (DE). **TRAUTWEIN, Mark** [DE/DE]; Nelkenweg 2, 42489 Wülfrath (DE). **GREVEN, Simone** [DE/DE]; Am Schneckenacker 45, 41541 Dormagen (DE). **WILMEN, Andreas** [DE/DE]; Arndtstr. 5, 50676 Köln (DE).

(74) Agent: **Bayer Intellectual Property GmbH**; Creative Campus Monheim, Geb. 4865, Alfred-Nobel-Str. 10, 40789 Monheim (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2012/163932 A1

(54) **Title**: NEUTRALIZING PROLACTIN RECEPTOR ANTIBODY MAT3 AND ITS THERAPEUTIC USE

(57) **Abstract**: The neutralizing prolactin receptor antibody Mat3. and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen - resistant breast cancer. The antibody blocks prolactin receptor-mediated signalling.